<DOC>
	<DOCNO>NCT02982148</DOCNO>
	<brief_summary>This study design compare effectiveness intradermal injection subcutaneous injection methylene blue early-stage breast cancer patient need sentinel lymph node biopsy .</brief_summary>
	<brief_title>Methylene Blue Intradermal Injection Sentinel Lymph Node Biopsy Breast Cancer Patients</brief_title>
	<detailed_description>After fully inform consent , patient recruit would randomize 1:1 intradermal injection group subcutaneous injection group . Investigators aim find difference sentinel lymph node detect rate , blue lymphatic detect rate complication incidence two group .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Methylene Blue</mesh_term>
	<criteria>sign inform consent form pathological diagnose , without distant metastasis , early stage invasive breast cancer patient undergo neoadjuvant chemotherapy , endocrinotherapy target therapy previously without breast axillary surgery history Ejection fraction score normal range accord cardiac doppler Eastern Cooperative Oncology Group score â‰¤02 axillary lymph node clinical negative pregnancy history malignant tumor within five year diagnosis multicenter , multifocal bilateral breast cancer history breast tumor incision biopsy vacuumassisted biopsy methylene blue allergic appear severe systematic disease disfunction organ</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>sentinel lymph node biopsy</keyword>
	<keyword>methylene blue</keyword>
	<keyword>intradermal injection</keyword>
	<keyword>subcutaneous injection</keyword>
</DOC>